Between 17 January and 23 January, 9,037 jobs were posted by 293 companies operating in the medtech market, according to GlobalData’s jobs analytics tool. This represented a 21% decrease in jobs posted compared to the previous week of 10 January to 16 January, when 11,411 listings were posted by 335 companies.
Of the 9,037 listings, the majority were at a junior or entry level, with almost 69% (6,200) falling into this category. Mid-senior jobs clocked in at 2,573, while 264 senior jobs were posted.
Of those companies hiring senior jobs, ThermoFisher Scientific had the most roles available, advertising 23 senior positions. These majority-US roles were largely concentrated outside of the laboratory, with the company seeking a senior director of business transformation, HR country leader and director of digital marketing operations.
The fact that ThermoFisher is advertising the majority of senior roles is unsurprising, as the firm had by far the most openings during the week at all levels, advertising for 740 new jobs across the board.
ThermoFisher is planning for the next pandemic
ThermoFisher has a number of roles available in asymptomatic testing solutions, with jobs available in nine locations across the US for senior product managers. Candidates will have the opportunity to work on developing products, technologies and service solutions designed to successfully manage pandemics by developing new products for the asymptomatic testing market.
The use of current polymerase chain reaction (PCR) and lateral flow tests (LFTs) to test for asymptomatic Covid-19 infection has been heavily criticised by some researchers, so a major medtech firm looking to develop improved asymptomatic testing products should be welcomed by the scientific community.
The move to hire asymptomatic test developers is unsurprising given Thermo Fisher’s recent deals activity – this month, the company acquired San Diego molecular diagnostics company Mesa Biotech for approximately $450m in cash, with up to an additional $100m on the table subject to certain conditions. Mesa has developed a PCR-based rapid point-of-case testing platform which can detect numerous infectious diseases including SARS-CoV-2, influenza A and B, respiratory syncytial virus (RSV) and strep A. Its patented technology expands the availability of high-standard nucleic acid PCR amplification to point-of-care testing.